Several Permax and Dostinex cases have been recently filed across the country for injuries involving valvular heart disease. These drugs were prescribed mainly for the treatment of Parkinson’s disease or Restless Leg Syndrome. However, articles and/or studies that were published in the New England Journal of Medicine in January, 2007, confirmed what earlier studies showed regarding a strong association between these drugs and heart valve damage. Specifically, these studies reported that users of these drugs had an increased risk of suffering from aortic, mitral, and/or tricuspid heart valve regurgitation. Heart valve regurgitation is the backward flow of blood across the heart valves causing damage to the heart ranging from congestive heart failure, heart valve replacement, and/or death. An ultrasound of a person’s chest, called an echocardiogram, is typically used to identify if any heart valve damage exists.
A March 2010 date has been set for the first Permax trial in the country, to be held in Miami, Florida against the makers of Permax and Pergolide (the generic form of Permax). This Florida Permax case involves a claimant who used Permax for over 50 months, which resulted in her suffering congestive heart failure and a mitral heart valve replacement. A second date in July, 2010 has been set for an additional Permax trial. This case is located in Colorado and involves a claimant who used Permax for over 20 months, which resulted in damage to her aortic heart valve.
There are a few other Permax, Dostinex, or combination cases that have already been filed or are in the process of being filed in Texas, Ohio, and Minnesota. Each of these claimants has used these drugs for an extended period of time and has suffered aortic, mitral, or tricuspid heart valve regurgitation. Additional trial dates are expected to be set in late 2010 and early 2011. If you want additional information, contact Navan Ward at 800-898-2034 or Navan.Ward@beasleyallen.com.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.